Sorry, you need to enable JavaScript to visit this website.

GREENSTONE LLC INTRODUCES VORICONAZOLE FOR ORAL SUSPENSION
Authorized Generic of Vfend®

PEAPACK, N.J., December 2013 — Greenstone LLC, a U.S.-based generic pharmaceutical subsidiary of Pfizer Inc. (NYSE: PFE), is pleased to announce the introduction of Voriconazole for Oral Suspension to its ever-expanding generic pharmaceutical product line. The product is offered in dosage strengths of 40mg/mL bottle.

Greenstone’s Voriconazole for Oral Suspension product is the authorized generic of, and equivalent to the innovator’s product, Vfend® (Voriconazole for Oral Suspension). This new authorized generic adds to Greenstone’s consistently growing line of products, and is backed by the power and scale of Pfizer’s 163-year worldwide reputation for a commitment to integrity, quality, and supply reliability. As a subsidiary of Pfizer, Greenstone operates under the same values and commitment to bring quality authorized generics to customers, payers, and the patients it serves.

See the Full Prescribing Information, for Greenstone’s Voriconazole for Oral Suspension at http://www.greenstonellc.com/product-list.aspx. For more information about Greenstone LLC and its products, visit http://greenstonellc.com.